Piper Jaffray analyst Edward Tenthoff lowered his price target for ChemoCentryx (CCRX) to $17 from $20 after its competitor InflaRx (IFRX) reported negative Phase IIb data for C5a antibody IFX-1 to treat moderate-to-severe hidradenitis suppurativa. ChemoCentryx shares are down because the company has its own small molecule avacopan targeting C5a receptor in an ongoing Phase II hidradenitis suppurativa study with data in 2020, Tenthoff tells investors in a research note. The analyst says that while nuances exist between InflaRx's IFX-1 and ChemoCentryx's avocopan for receptor coverage and distribution, the lack of dose response in InflaRx's Phase II data raises concern over the relevancy of C5a in hidradenitis suppurativa. As a result, Tenthoff removed value for avacopan in hidradenitis suppurativa in his model but remains a buyer of ChemoCentryx shares for the Phase III Advocate avacopan data in ANCA-associated vasculitis in Q4 of this year. He keeps an Overweight rating on the shares, which are down 17% to $9.18 in afternoon trading.